Applications published 29 July 2009

Methods related to peripheral administration of NOGO receptor polypeptides
Biogen Idec; Yale University 2081429*

• Salt forms of substituted benzothienyl compounds
Janssen Pharmaceutica 2081430*

• Organic compounds
Intra-Cellular Therapies 2081431*

• Triazolpyrimidine derivatives as ADP P2Y12 receptor antagonists
Janssen Pharmaceutica 2081433*

• Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
Janssen Pharmaceutica 2081434*

• Inhibitors of bruton's tyrosine kinase
Pharmacyclics 2081435*

• Reconstitution device for injectable medication
Duoject Medical Systems 2081540*

• Microencapsulated photo-initiators and the use thereof for dental materials
Ivoclar Vivadent 2081541*

• Methods of producing microparticles
CMP Therapeutics 2081545*

• Multiple unit tablet compsns of benzimidazole compounds
Ranbaxy Laboratories 2081546*

• Galenic form for the transmucosal delivery of active ingredients
Perovitch, Phillipe; Maury, Marc 2081547*

• Compsns and methods for pH targeted drug delivery
Labopharm; Labopharm Europe; Labopharm (Barbados) 2081548*

• Ophthalmic compsns containing diglycine
Bausch & Lomb 2081549*

• Pharmaceutical capsules with active pharmaceutical ingredients
Reliant Pharmaceuticals 2081550*

• Dried reconstituted vesicle formation for pharmaceutical application
Scil Technology 2081551*

• Spontaneously forming ellipsoidal phospholipid unilamellar vesicles
Children's Hospital Medical Centre 2081552*

• Stable antibody formulations
Amgen 2081553*

• Atorvastatin pharmaceutical compsns
Dr Reddy's Laboratories Ltd; Dr Reddy's Laboratories Inc 2081554*

• Pharmaceutical compsns for the oral or rectal administration of protein substances
Cosmo Technologies 2081555*

• Stable Imatinib compsns
Teva Pharmaceutical Industries; Teva Pharmaceutical USA 2081556*

• Colonic delivery using ZN/pectin beads with a eudragit coating
DA Volterra 2081557*

• Method of weight control using chewing gum
WM Wrigley 2081558*

• Procedure and devices for the controlled obtaining of dry saline aerosols with therapeutic effect
Pascu, Constantin 2081559*

• Treatment of gastrointestinal diseases
The University of Manchester 2081560*

• Methods and compsns using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases
Celgene 2081561*

• Methods for delivering volatile anaesthetics for regional anaesthesia and/or pain relief
The Board of Regents of the University of Texas System 2081562*

• Pharmaceutical formulations
Abbott Laboratories 2081563*

• Use of citrulline for treating undernutrition conditions
Universite Rene Descartes Paris; Biocodex 2081564*

• Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
Reliance Life Sciences 2081565*

• Improved biological effects of compsns comprising rosmarinic acid
Nestec; L'Oreal 2081566*

• Compsns containing zinc salts for coating medical articles
The trustees of Columbia University in the City of New York; VSP Technologies 2081568*

• Compsns therapy with SGLT-2 inhibitors and their pharmaceutical compsns
Boehringer Ingelheim 2081569*

• Anti-resorptive and bone building dietary supplements and methods of use
Krempin, David; Murray, Mary; Lin, Yumei; Gellenbeck, Kevin; Da Costa, Silvia; Wilkins, Leon; Roh-schmidt, Haeri; Rana, Jatinder; Rebhun. John; Fast, David 2081570*

• Mixed oral 1/µ agonists for treating pain
Gruenenthal 2081571*

• Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
Janssen Pharmaceutica 2081572*

• Use of a pharmaceutical compsn comprising an anticholinergic for killing microorganisms and for treating respiratory tract infections
Boehringer Ingelheim Pharma 2081573*

• Buprenophine-containing non-pressurised spray compsn for transmucosal administration
Pharmasol 2081574*

• Allosteric modulators of the A1 adenosine receptor
King Pharmaceuticals Research and Development 2081575*

• Method of improving bioavailability for non-sedating barbiturates
Taro Pharmaceuticals North America 2081576*

• Prostaglandin E2 (PGE2) as an adjuvant in monoclonal antibody generation
Centocor Ortho Biotech 2081577*

• Combination of a glucocorticoid and a beta-cyclodextrin conjugated vitamin A derivative complex
Pharma Medico Research 2081578*

• Food supplement agent based on rock
Oberboersch, Michel 2081579*

• Polyethylene glycol-G-CSF conjugate
Dong-A Pharmaceutical 2081580*

• Antimicrobial articles and method of manufacture
3M Innovative Properties 2081581*

• Rosemary extracts, dietary and pharmaceutical compsns containing them and their uses
DSM IP 2081582*

• Treatment of inflammation, demyelination and neuronal/axonal loss
Government of the United States of America as represented by the Secretary of the Department of Health and Human Services 2081584*

• Cancer treatment
The Regents of the University of California 2081585*

• Respondins as modulators of angiogenesis and vasculogenesis
Deutsches Krebsforschungszentrum 2081586*

• Alpha-MSH Therapies for treatment of autoimmune disease
Research Development Foundation 2081587*

• Antimicrobial compsn and uses thereof
Perraudin, Jean-Paul 2081588*

• Complementation of factor XI deficiency by factor V mutants
Crucell Holland; Van den Nieuwenhof, Ingrid 2081589*

• Cancer stem cell-targeted cancer therapy
Stemline Therapeutics 2081590*

• Method for generating active antibodies against a resistance antigen, antibodies obtained by said method, and their uses
Pierre Fabre Medicament 2081592*

• Novel method for treating H pylori infections
Gerhard, Markus 2081594*

• Combination treatment of CD38-expressing tumours
Genmab 2081595*

• Method of detecting ocular diseases and pathologic conditions and treatment of same
University of Utah Research Foundation 2081596*

• Bioavailable combinations for HCV treatment
Tibotec Pharmaceuticals 2081598*

• Combination of NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
Laboratoires del Dr Esteve 2081600*

• Dendrimeric platform for controlled release of drugs
Ariel-University Research & Development 2081601*

• Toxin peptide therapeutic agents
Amgen 2081602*

• Method of preventing or treating metabolic syndrome
Dow Global Technologies; United States Department of Agriculture 2081647*

• Carbamate compounds for use in treating depression
Janssen Pharmaceutica 2081648*

• Modulation of CD1B or CD1D expression in autoimmune disorders
Novartis 2081649*

• N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
Novartis 2081888*

• Sulphonamide derivatives
F Hoffmann-La Roche 2081889*

• Arylsulphonamide pyrrolidines as 5-HTg inhibitors
F Hoffmann-La Roche 2081890*

• Pharmaceutical compounds having HSP90 inhibitory or modulating activity
Astex Therapeutics 2081891*

• Compounds and methods for treating protein folding disorders
Queen's University and Kingston 2081892*

• Substituted indoles
Auspex Pharmaceuticals 2081893*

• 1H-indole-2-carboxylic acid derivatives useful as PPAR modulators
SmithKline Beecham 2081894*

• Hydrobenzamide derivatives as inhibitors of HSP90
Astex Therapeutics 2081895*

• Benzoisoin derivatives and their use as EP4 receptor agonists
Glaxo Group 2081896*

• Isoindol derivatives as EP4 receptor agonists
Glaxo Group 2081897*

• Adamantylurea compounds as soluble epoxide hydrolase inhibitors
Arete Therapeutics 2081898*

• Alternate process for remifentanil preparation
Mallinckrodt 2081899*

• New N-(3-pyridin-2-ylpropyl)benzamide derivatives
Bayer CropScience 2081900*

• Novel 2-amino-pyridine derivatives and their use as potassium channel modulators
NeuroSearch 2081901*

• Polymorph III of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
Bayer Schering Pharma 2081902*

• 2-aminocarbonyl-pyridine derivatives
Actelion Pharmaceuticals 2081903*

• Ariprazole hemifumarate and process for its preparation
Krka Tovarna Zdravil 2081904*

• Sulphonyl compounds which modulate the CB2 receptor
Boehringer Ingelheim International 2081905*

• Sitamaquine tosylate for the treatment of leishmaniasis
Glaxo Group 2081906*

• Aryl piperazine derivatives useful for the treatment of neuropsychiatry disorders
Universita Degli Studi di Siena 2081907*

• Process for the sulphinylation of a pyrazole derivative
BASF 2081908*

• Process for the sulphinylation of a pyrazole derivative
BASF 2081909*

• Novel compounds
Glaxo Group 2081910*

• Bicyclic heteroaromatic compounds
Glaxo Group 2081915*

• Oxadiozole derivatives with anti-inflammatory and immunosuppressive properties
Novartis 2081916*

• Cytochrome p450 oxidase inhibitors and uses thereof
Abbott Laboratories 2081917*

• Mitotic kinesin inhibitors and methods of use thereof
Array Biopharma 2081918*

• Tetrahydrofuro [3,2-B] pyrrol-3-one intermediates
Amura Therapeutics 2081919*

• Method for preparing crystalline 3-O-alkyl-ascorbic acid
Cosmol 2081920*

• Short-acting benzodiazepine salts and their polymorphic forms
Paion2 2081921*

• 5,6-ring annulated indole derivatives and use thereof
Schering 2081922*

• Certain substituted amides, method of making and method of use thereof
CGI Pharmaceuticals 2081923*

• Small molecule inhibitors of toll-like receptor 9
Coley Pharmaceutical 2081924*

• Preparation and purification of mupirocin calcium
Axellia Pharmaceuticals 2081926*

• Piperidine derivatives as renin inhibitors
Vitae Pharmaceuticals 2081927*

• Pyrrolo-pyridine kinase inhibitors
Bristol-Myers Squibb 2081928*

• Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyridoy2,1-A isoquinolin-2-ol compounds and methods relating thereto
Neurocrine Biosciences 2081929*

• Kinase inhibitors
Takeda San Diego 2081930*

• Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor
Amgen 2081931*

• 2-O"-methyladenosine derivatives and their use as agonists or antagonists of an adenosine receptor
Biovitrum 2081932*

• Pyrazolopyrimidines as P13K lipid kinase inhibitors
Novartis 2081933*

• Process for the manufacture of a crystalline pyrazolo[1,5-A]pyrimidine compound
Ferrer Internacional 2081934*

• Polymorph B of N-{2-fluoro-5-[3-(thiphene-2-carbonyl)-pyrazolo[1,5-A]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide
Ferrer Internacional 2081935*

• Pyrrolotriazine kinase inhibitors
Bristol-Myers Squibb 2081936*

• Triazolopyridazine protein kinase modulators
SGX Pharmaceuticals 2081937*

• Benzimidazole derivatives as selective acid pump inhibitors
RaQualia Pharma 2081939*

• Process for preparation of prulifloxacin using novel intermediates
Hetero Drugs 2081940*

• Mercapto-functional silane compsns having reduced VOC levels
Momentive Performance Materials 2081941*